GS
UTHR icon

GAM Systematic’s United Therapeutics UTHR Stock Holding History

GAM Systematic’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$2.14M Buy
18,270
+2,734
+18% +$349K 0.31% 93
2017
Q2 		$2.02M Buy
15,536
+3,766
+32% +$470K 0.29% 102
2017
Q1 		$1.59M Buy
11,770
+1,308
+13% +$198K 0.31% 89
2016
Q4 		$1.5M Sell
10,462
-911
-8% -$116K 0.35% 60
2016
Q3 		$1.34M Buy
11,373
+993
+10% +$119K 0.28% 100
2016
Q2 		$1.1M Sell
10,380
-40
-0.4% -$4.46K 0.26% 126
2016
Q1 		$1.16M Buy
10,420
+388
+4% +$49.1K 0.31% 102
2015
Q4 		$1.57M Sell
10,032
-2,651
-21% -$386K 0.45% 21
2015
Q3 		$1.67M Sell
12,683
-20,852
-62% -$3.34M 0.39% 39
2015
Q2 		$5.83M Buy
33,535
+7,083
+27% +$1.27M 0.74% 16
2015
Q1 		$4.56M Buy
26,452
+6,408
+32% +$977K 0.63% 18
2014
Q4 		$2.6M Buy
+20,044
New +$2.58M 0.53% 43

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GAM Systematic's UTHR Position: Q3 2017 in Review

GAM Systematic increased its United Therapeutics (UTHR) stake by 18% in Q3 2017, buying an estimated $349K and bringing the position to 18,270 shares worth $2.14M. The position accounts for 0.31% of the portfolio, ranked #93.

GAM Systematic first reported a position in UTHR in Q4 2014 and has held it in 12 quarters since. The position peaked at $5.83M in Q2 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • GAM Systematic held 18,270 shares of United Therapeutics worth $2.14M as of Q3 2017.
  • GAM Systematic bought 2,734 United Therapeutics shares in Q3 2017, an estimated $349K.
  • United Therapeutics made up 0.31% of GAM Systematic's portfolio in Q3 2017, its #93 holding.
  • GAM Systematic first reported a position in United Therapeutics in Q4 2014 and has held it in 12 quarters since.
  • GAM Systematic's United Therapeutics position peaked at $5.83M in Q2 2015.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on GAM Systematic's 13F filing for Q3 2017, filed 14 Nov 2017.